Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
ABBV: second_quarter 2026 lobbying report
Part B, Part D, drug pricing and access, negotiation, federal budget issues drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
Public: Jul 20, 2026, 10:07 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implement
Public: Jul 20, 2026, 5:03 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monit
Public: Jul 20, 2026, 2:49 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
Medicare Implementation of the Inflation Reduction Act. Issues around drug pricing. Education and legislation related to reform of the 340(b) program. Education around data privacy.
Public: Jul 20, 2026, 2:33 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Jul 18, 2026, 1:39 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
Issues regarding life sciences related matters. Issues regarding life sciences related matters.
Public: Jul 15, 2026, 12:30 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Public: Jul 9, 2026, 6:27 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues.
Public: Jul 7, 2026, 1:58 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined not to review an initial determination ("ID") (Order No. 17) of the presiding administrative law judge ("ALJ"), terminating this investigation in its entirety based on withdrawal of the complaint.
Public: Jul 7, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Financial results
Filed 8-K for an event or period dated 2026-07-06. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Public: Jul 6, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYALEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Public: Jun 29, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that RECTIV (nitroglycerin) ointment, 0.4%, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Public: Jun 26, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Company disclosure
Filed 8-K for an event or period dated 2026-06-18. Company disclosure.
1 congressional household disclosed purchases in the past 90 days. See the trades
Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
Public: Jun 8, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 16 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Public: Jun 3, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: 8-K company filing
Filed 8-K for an event or period dated 2026-05-08. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:16 PM EST
- USAspending
- Collection in progress72 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Federal Register
- Collection in progress298 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST